Healthcare Technology
GRAIL’s Galleri Test Heads to FDA Panel After Staff Review
GRAIL Inc. (Nasdaq: GRAL) is scheduled to bring its Galleri multi-cancer blood test before a U.S. Food and Drug Administration advisory panel on September 23, 2026, following the release of agency briefing materials that identified no outstanding panel questions in several core review areas. The FDA’s Molecular and Clinical Genetics Panel will discuss and vote…
Telo Genomics Reports Higher MRD Detection in Myeloma Study
Telo Genomics Corp. (TSXV: TELO; OTCQB: TDSGF) has reported clinical research results showing that its experimental blood-based TELO-MRD assay detected residual multiple myeloma cells in a higher proportion of matched samples than a bone-marrow test. The September 15 announcement covered 42 samples matched by patient and collection date. TELO-MRD detected circulating myeloma cells in 39…
Inside the Federal Review That Could Reshape Lab AI
Federal regulators are reconsidering how a set of lab-testing rules written in 1992 should handle artificial intelligence, and the group representing the country’s clinical lab professionals just weighed in. The outcome could matter for investors well beyond any one company: the two largest publicly traded U.S. commercial labs, plus at least one AI-native diagnostics company,…
What Are Organoids? The Lab-Grown “Mini-Organs” Changing Drug Testing
Traditional preclinical drug testing has relied heavily on two-dimensional cell cultures — cells grown as a flat layer in a laboratory dish — and animal models, both of which imperfectly represent how a drug will actually behave in complex human tissue. Organoids offer a fundamentally different approach: three-dimensional, lab-grown tissue structures that self-organize to mimic…
Inside St. Joseph’s New AI-Powered Chest CT Reading Tool
Coreline Soft, a South Korean medical AI company that trades on the KOSDAQ exchange under ticker 384470, and INFINITT North America announced on August 21 the deployment of a chest CT-based AI reading workflow at St. Joseph’s Health, an academic hospital system in Paterson, New Jersey. It is the second major North American deployment for…
What Is RNA Interference (RNAi)? The Gene-Silencing Technology Powering a New Drug Class
While CRISPR captured public attention for editing DNA directly, a related but mechanistically distinct technology quietly built its own approved drug class by intervening one step later in the gene expression process — at the RNA level rather than the DNA level. RNA interference (RNAi) therapeutics silence specific disease-causing genes by preventing their RNA instructions…
What Are Digital Biomarkers? How Wearable Technology Is Entering Drug Development
Clinical trials have traditionally measured patient outcomes through periodic clinic visits — a blood pressure reading, a questionnaire, a physical exam, captured at scheduled intervals weeks or months apart. Digital biomarkers offer a fundamentally different approach: continuous, objective measurement of a patient’s health status using wearable devices and sensors, generating far richer data than intermittent…
PharmaTher Establishes PERSONALIZ3D Personalized Medicine Platform
PharmaTher Holdings Ltd. (CSE: PHRM; OTCQB: PHRRF) is a Toronto-based life sciences company focused on personalized medicines and pharmaceutical 3D-printing technologies. The Canadian Securities Exchange lists 91,019,065 shares issued and outstanding. In its latest publicly available interim financial statements, the company reported C$794,804 in cash and no revenue to date as of February 28, 2026.…
Karyopharm Plans August FDA Filing for Selinexor Combination
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, plans to submit a supplemental New Drug Application to the U.S. Food and Drug Administration in August 2026 for selinexor in combination with ruxolitinib as a treatment for myelofibrosis. The company said it will seek accelerated approval following discussions with the FDA.…
HLS Secures Broad Private Coverage for NILEMDO Across Canada
HLS Therapeutics Inc. (TSX: HLS), a specialty pharmaceutical company focused on cardiovascular and psychiatric treatments, has expanded Canadian reimbursement access for NILEMDO, its oral cholesterol-lowering medication. The company said it has secured reimbursement agreements with Canada’s largest private payers, which it estimates represent approximately 80% of privately insured Canadians. Most patients covered by those plans…
